Impetigo Drugs

Impetigo Drugs

Global Impetigo Drugs Market to Reach US$2.1 Billion by 2030

The global market for Impetigo Drugs estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Fusidane Drug, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$883.5 Million by the end of the analysis period. Growth in the Quinolones Drug segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.1 Million While China is Forecast to Grow at 7.5% CAGR

The Impetigo Drugs market in the U.S. is estimated at US$422.1 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$432.8 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Impetigo Drugs Market - Key Trends and Drivers Summarized

Impetigo is a highly contagious bacterial skin infection that primarily affects infants and young children, though it can occur in individuals of any age. The infection is caused by Staphylococcus aureus or Streptococcus pyogenes and is characterized by red sores that quickly rupture, ooze for a few days, and then form a yellowish-brown crust. Impetigo is typically treated with antibiotics, either topically applied directly to the sores or taken orally in more severe cases. The most commonly prescribed topical antibiotics include mupirocin and fusidic acid, while oral antibiotics such as penicillin, erythromycin, and cephalexin are used for more extensive infections. The choice of treatment depends on the severity of the infection, the patient`s age, and any underlying health conditions.

Recent advancements in the development of impetigo drugs have focused on improving the efficacy and reducing the resistance of bacterial strains to existing treatments. Researchers are working on new formulations and delivery systems to enhance the penetration and effectiveness of topical antibiotics. Moreover, there is growing interest in combination therapies that utilize both topical and oral antibiotics to combat severe or resistant infections. Advances in molecular biology and genomics have also enabled the identification of novel antibiotic targets, leading to the development of new drug candidates that can potentially overcome resistance mechanisms. These innovations are critical as the prevalence of antibiotic-resistant bacteria continues to rise, posing significant challenges to effective impetigo management.

The growth in the impetigo drugs market is driven by several factors. The increasing incidence of impetigo, particularly in regions with warm, humid climates and crowded living conditions, has heightened the demand for effective treatments. Technological advancements in drug delivery systems, such as liposomal and nanoparticle formulations, have expanded the addressable market by offering improved drug stability and targeted delivery. The rise in antibiotic resistance has spurred the development of new antibiotics and combination therapies, which are crucial for maintaining the efficacy of impetigo treatments. Additionally, greater awareness of impetigo symptoms and the importance of early treatment among parents and healthcare providers is driving market demand. The expansion of healthcare infrastructure in emerging markets, along with increased healthcare spending, is also contributing to market growth. Furthermore, regulatory support for the development of new antibiotics and expedited approval processes for critical drugs are facilitating the entry of new treatments into the market. Collectively, these factors are fostering a dynamic and rapidly evolving market for impetigo drugs.

Select Competitors (Total 86 Featured) -
  • Grupo Ferrer Internacional, S.A.
  • GSK Plc
  • Laboratorios Ojer Pharma S.L.
  • LEO Pharma A/S
  • Lytix Biopharma AS
  • Medimetriks Pharmaceuticals, Inc.
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • UNION therapeutics A/S
  • Vaxcyte;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Impetigo Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Impetigo Spurs Demand for Effective Treatments
Technological Advancements in Drug Delivery Propel Growth
Development of Novel Antibiotics Expands Addressable Market Opportunity
Increasing Antibiotic Resistance Strengthens Business Case for New Treatments
Here`s How Combination Therapies Generate New Market Opportunities
Advances in Molecular Biology and Genomics Propel Innovation in Drug Development
Growing Healthcare Spending in Emerging Markets Sustains Growth
Increasing Number of Clinical Trials Validating Efficacy and Safety of New Drugs Drive Market Confidence
Economic Burden of Skin Infections Strengthens Business Case for Effective Solutions
Here`s the Story: Impact of Pediatric and Geriatric Populations on Market Demand
Rising Adoption of Topical Antibiotics Drives Market Growth
Expansion of Online Pharmacies Expands Access to Impetigo Drugs
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Impetigo Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Fusidane Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Quinolones Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Sulfonamide Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Tetracycline Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
JAPAN
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: Japan 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
CHINA
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: China Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: China 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
EUROPE
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
FRANCE
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: France Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: France 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
GERMANY
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: Germany 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Italy 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
UNITED KINGDOM
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: UK Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: UK 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: Spain 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Russia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Rest of Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
AUSTRALIA
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 65: Australia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: Australia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: Australia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
INDIA
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 68: India Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: India Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: India 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 71: South Korea Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: South Korea Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: South Korea 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Rest of Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
LATIN AMERICA
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 77: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Latin America 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 80: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 83: Argentina Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: Argentina Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: Argentina 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
BRAZIL
TABLE 86: Brazil Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Brazil Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Brazil 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
MEXICO
TABLE 89: Mexico Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Mexico Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Mexico 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
MIDDLE EAST
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 95: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Middle East 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 98: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
IRAN
TABLE 101: Iran Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Iran Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Iran 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
ISRAEL
TABLE 104: Israel Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 105: Israel Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Israel 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Saudi Arabia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Saudi Arabia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 110: UAE Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: UAE Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: UAE 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: Rest of Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: Rest of Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
AFRICA
Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 116: Africa Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Africa Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: Africa 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings